(Q36498695)
Statements
1 reference
Comparison of safety and tolerability with continuous (exenatide once weekly) or intermittent (exenatide twice daily) GLP-1 receptor agonism in patients with type 2 diabetes (English)
1 reference
T Ridge
1 reference
T Moretto
1 reference
L MacConell
1 reference
R Pencek
1 reference
J Han
1 reference
C Schulteis
1 reference
L Porter
1 reference
19 July 2012
1 reference
1 reference
1097-1103
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference
1 reference
1 reference